Evidence map›Paper›PMID 28470406›Full record

ArticleEJNMMI research2017

Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using

Zohreh Varasteh, Fabien Hyafil, Nadège Anizan, Devy Diallo, Rachida Aid-Launais, Sarajo Mohanta, Yuanfang Li, Miriam Braeuer, Katja Steiger, Jonathan Vigne and 8 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in EJNMMI research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04663126 (Pilot Study to Test the Feasibility of IV Injected Tc-99m-tilmanocept for Imaging of M2-like Tumour Associated Macrophages in Metastatic Melanoma), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04663126 early_phase1terminatednot on this mapstarted 2021, after this paper: background citation

Pilot Study to Test the Feasibility of IV Injected Tc-99m-tilmanocept for Imaging of M2-like Tumour Associated Macrophages in Metastatic Melanoma

TypeinterventionalSponsorJohn O. PriorRan2021 to 2023Enrolled5ConditionsMelanomaArmsTc-99m tilmanocept
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Single Photon Emission Computed Tomography Tracer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  8. PET/MR imaging of inflammation in atherosclerosis.Nature biomedical engineering · 2023
    Review
  9. Article
  10. Review
  11. Re-engineered imaging agent using biomimetic approaches.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022
    Review
  12. Article
  13. Review
  14. Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021
    Article
  15. Article
  16. Current and novel radiopharmaceuticals for imaging cardiovascular inflammation.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... · 2020
    Review
  17. Clinical Translation of [Molecular imaging and biology · 2019
    Article
  18. Imaging inflammation in atherosclerotic plaques: Just make it easy!Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019
    Article
  19. Antibody-Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases.Chembiochem : a European journal of chemical biology · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 3 countries.

Zohreh VarastehDepartment of Nuclear Medicine, Klinikum rechts der Isar der TUM, Ismaningerstrasse 22, 81675, Munich, Germany. zohreh.varasteh@tum.de.
Fabien HyafilDepartment of Nuclear Medicine, Hôpital Bichat, Paris, France.
Nadège AnizanFédération de Recherche en Imagerie Multimodalité, Université Paris Diderot, Paris, France.
Devy DialloFédération de Recherche en Imagerie Multimodalité, Université Paris Diderot, Paris, France.
Rachida Aid-LaunaisINSERM U1148 Laboratory of Vascular Translational Science, Paris, France.
Sarajo MohantaInstitute for Cardiovascular Prevention, University Hospital of Ludwig-Maximilians-University, Munich, Germany.
Yuanfang LiInstitute for Cardiovascular Prevention, University Hospital of Ludwig-Maximilians-University, Munich, Germany.
Miriam BraeuerDepartment of Nuclear Medicine, Klinikum rechts der Isar der TUM, Ismaningerstrasse 22, 81675, Munich, Germany.
Katja SteigerInstitute of Pathology, Technische Universität München, Munich, Germany.
Jonathan VigneDepartment of Nuclear Medicine, Hôpital Bichat, Paris, France.
Zhengtao QinUCSD Moores Cancer Center, University of California, San Diego, La Jolla, USA.
Stephan G NekollaDepartment of Nuclear Medicine, Klinikum rechts der Isar der TUM, Ismaningerstrasse 22, 81675, Munich, Germany.
Jean-Etienne FabreINSERM U1148 Laboratory of Vascular Translational Science, Paris, France.
Yvonne DöringInstitute for Cardiovascular Prevention, University Hospital of Ludwig-Maximilians-University, Munich, Germany.
Dominique Le GuludecDepartment of Nuclear Medicine, Hôpital Bichat, Paris, France.
Andreas HabenichtInstitute for Cardiovascular Prevention, University Hospital of Ludwig-Maximilians-University, Munich, Germany.
David R VeraUCSD Moores Cancer Center, University of California, San Diego, La Jolla, USA.
Markus SchwaigerDepartment of Nuclear Medicine, Klinikum rechts der Isar der TUM, Ismaningerstrasse 22, 81675, Munich, Germany.
Ludwig-Maximilians-Universität München · DEHôpital Bichat-Claude-Bernard · FRKlinikum rechts der Isar · DELaboratoire de Recherche Vasculaire Translationnelle · FRUniversity of California San Diego · USFédération de recherche en imagerie multi-modalité · FRGerman Centre for Cardiovascular Research · DEImagerie par Résonance Magnétique Médicale et Multi-Modalités · FRTechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtherosclerotic plaque phenotypes are classified based on the extent of macrophage infiltration into the lesions, and the presence of certain macrophage subsets might be a sign for plaque vulnerability. The mannose receptor (MR) is over-expressed in activated macrophages. Tilmanocept is a tracer that targets MR and is approved in Europe and the USA for the detection of sentinel lymph nodes. In this study, our aim was to evaluate the potential of

methodsTilmanocept was labelled with

results

conclusionsAfter i.v. injection,

Indexed as

AtherosclerosisInflammationM2 differentiated macrophagesNon-invasive imagingSPECT/CTTilmanocept

Identifiers

PMID28470406
PMCPMC5415447
OpenAlexW2611458780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.